BIO-TECHNE ($TECH) posted quarterly earnings results for Q3 2026 on Wednesday, May 6th. The company reported earnings of $0.53 per share, missing estimates of $0.55 by $0.02. The company also reported revenue of $311,420,000, missing estimates of $323,434,778 by $-12,014,778.
You can see Quiver Quantitative's $TECH stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIO-TECHNE Insider Trading Activity
BIO-TECHNE insiders have traded $TECH stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TECH stock by insiders over the last 6 months:
- AMY E. HERR sold 1,976 shares for an estimated $116,791
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
BIO-TECHNE Hedge Fund Activity
We have seen 259 institutional investors add shares of BIO-TECHNE stock to their portfolio, and 303 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 2,495,328 shares (+164.4%) to their portfolio in Q4 2025, for an estimated $146,750,239
- MACQUARIE GROUP LTD removed 1,824,428 shares (-99.6%) from their portfolio in Q4 2025, for an estimated $107,294,610
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,801,049 shares (-81.0%) from their portfolio in Q4 2025, for an estimated $105,919,691
- ALLIANCEBERNSTEIN L.P. added 1,447,516 shares (+157.8%) to their portfolio in Q4 2025, for an estimated $85,128,415
- BAMCO INC /NY/ removed 1,288,824 shares (-51.6%) from their portfolio in Q4 2025, for an estimated $75,795,739
- SG CAPITAL MANAGEMENT LLC added 1,149,129 shares (+inf%) to their portfolio in Q4 2025, for an estimated $67,580,276
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,138,721 shares (-97.2%) from their portfolio in Q4 2025, for an estimated $66,968,182
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
BIO-TECHNE Congressional Stock Trading
Members of Congress have traded $TECH stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $TECH stock by members of Congress over the last 6 months:
- REPRESENTATIVE APRIL MCCLAIN DELANEY has traded it 5 times. They made 2 purchases worth up to $30,000 on 12/05, 12/02 and 3 sales worth up to $45,000 on 03/26, 02/24, 01/28.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
BIO-TECHNE Analyst Ratings
Wall Street analysts have issued reports on $TECH in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Argus Research issued a "Buy" rating on 11/20/2025
To track analyst ratings and price targets for BIO-TECHNE, check out Quiver Quantitative's $TECH forecast page.
BIO-TECHNE Price Targets
Multiple analysts have issued price targets for $TECH recently. We have seen 7 analysts offer price targets for $TECH in the last 6 months, with a median target of $76.0.
Here are some recent targets:
- Daniel Markowitz from Evercore ISI Group set a target price of $54.0 on 04/06/2026
- Brandon Couillard from Wells Fargo set a target price of $76.0 on 02/06/2026
- Kyle Boucher from TD Cowen set a target price of $80.0 on 02/05/2026
- Dan Leonard from UBS set a target price of $79.0 on 02/05/2026
- Daniel Arias from Stifel set a target price of $65.0 on 02/05/2026
- Patrick Donnelly from Citigroup set a target price of $80.0 on 02/05/2026
- David Toung from Argus Research set a target price of $68.0 on 11/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
